by Global Botulinum Toxin Market – Snapshot
The global botulinum toxin market was valued at US$ 4,527.0 Mn in 2017 and is projected to reach US$ 8,718.7 Mn by 2026, expanding at a CAGR of 7.6% from 2018 to 2026. Increase in the prevalence of spasticity and cervical dystonia and the number of cases of migraine is expected to drive the botulinum toxin market during the forecast period. Surge in the rate of adoption of non-surgical botulinum toxin procedures, due to their noninvasive or minimally invasive nature, is boosting botulinum toxin market. Rise in the number of worldwide geriatric population and incidences of esthetic issues, such as crow’s foot and lateral canthal lines, is a key factor that is anticipated to propel the botulinum toxin market during the forecast period. However, lack of awareness regarding the advancements in non-surgical esthetic and therapeutic procedures is a major factors hampering revenue generation in the global botulinum toxin market.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111974
The global botulinum toxin market has been segmented into product type, application, and region. In terms of product type, the market has been classified into botulinum toxin type A and botulinum toxin type B. The botulinum toxin type A segment held a prominent share of the global botulinum toxin market in 2017. Increase in prevalence of cervical dystonia, spasticity, glabellar lines, and crow’s foot and rise in the use of botulinum toxin type A are key factors driving the market. The botulinum toxin type B segment is expected to expand at a considerable CAGR during the forecast period. Advantages of botulinum toxin type B, such as faster onset of action and faster recovery time, and introduction of new and improved type B products in the market for new indications are major factors propelling the segment. Based on application, the global botulinum toxin market has been segregated into esthetic and therapeutics. The therapeutics segment dominated the global botulinum toxin market in 2017, owing to global rise in the cases of migraine and increase in the demand for non-surgical therapeutic procedure, which is noninvasive or minimally invasive in nature. The esthetic segment is anticipated to expand at a higher CAGR during the forecast period, owing to the increase in prevalence of lateral canthal lines and face wrinkles.
Based on region, the global botulinum toxin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global botulinum toxin market in 2017, owing to the rise in awareness level regarding non-surgical esthetic and therapeutic procedures. The botulinum toxin market in North America is expected to maintain its dominant position in the global market during the forecast period. The botulinum toxin market in Europe is expected to expand during the forecast period, due to increase in geriatric population. The market in Asia Pacific is projected to expand at a comparatively higher CAGR during the forecast period, owing to the rise in adoption of non-surgical botulinum toxin procedures by the geriatric population and favorable government regulations.
Prominent players operating in the global botulinum toxin market include Allergan, Inc., Ipsen Group, Merz Pharma GmbH & Co. KGaA, Medytox, Inc., US Worldmed, LLC, Galderma, Metabiologics, Inc. (US), Lanzhou Institute of Biological Products Co. Ltd. and Revance Therapeutics, Inc. Allergan, Inc., Ipsen Group, and Merz Pharma GmbH & Co. KGaA are the prominent global market players in the botulinum toxin market. Allergan, Inc. has strong regional presence, either direct or through subsidiaries, distributors, and partnerships. Extensive research & development, international presence, robust marketing, and product reliability, provide the company, an upper hand over its competitors.
Next-Generation Sequencing Technologies Bolster Botulinum Toxin Market
There has been some fascinating research in utilizing the biologic and pharmacological properties of botulinum toxin (BT) in medical sciences. Amusingly, it is the first biological toxin that has found its way to disease biology, opening up massive vistas of possibilities for healthcare companies. The use of next-generation sequencing technologies has helped propelled the strides in the botulinum toxin (BT) market. Among the various subtypes of BT, the use of subtype A for botulinum neurotoxin therapy has gained substantial attention among players. Researchers have been able to establish its remarkable safety and its potential for use in both injectable and oral form. This is a key driver for new avenues in the BT market. Botulinum neurotoxins (BoNT) is considered to be promising in numerous cosmetic and therapeutic interventions. A great deal of the progress has been fuelled by growing understanding of the pharmacology of BoNT. Some of the avenues where market players see potential revenue streams from the use of BT injections are in facial rejuvenation, in treating primary axillary hyperhidrosis, and hemimasticatory spasm. One of the promising therapeutic areas where BT is showing vast potential is being used as a therapeutic alternative for spasticity management which also includes poststroke spasticity.
The Covid-19 pandemic has been cause of substantial morbidity and mortality in worldwide populations. Recently emergent variants have caused havoc in some regions of the world. Policy makers in collaboration with industry players are keen on consolidating the logistics and supply chain of vaccine development to distribution to the last mile. Vaccine developers have been benefitting from favorable regulatory outlook. A recent case in point is approval of an array of vaccines. A great deal of the efforts in developing promising vaccine candidates for SARS-CoV-2 has been cemented by valuable learnings scientists and vaccine manufacturers have gained from SARS-CoV and MERS-CoV. The success that some nations have achieved in vaccinating people across different age groups has boosted consumer sentiment and is expected to bolster macroeconomic fundamentals.
The global botulinum toxin market has been segmented as follows:
Product Type
- Botulinum Toxin Type A
- Botulinum Toxin Type B
Application
- Aesthetic
- Therapeutics
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111974/2900
